Bone marrow aspirate and biopsy: A pathologist's perspective. II. Interpretation of the bone marrow aspirate and biopsy

Journal of Clinical Laboratory Analysis

Volumn 23, Issue 5, 2009, Pages 259-307

  Riley, Roger S ^a   Williams, David ^a   Ross, Micaela ^b   Zhao, Shawn ^c   Chesney, Alden ^d   Clark, Bradly D ^e   Ben Ezra, Jonathan M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JEWISH HOSPITAL   (United States)

^c Drug Information   (United States)

^d SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bone marrow examination; Bone marrow pathology; Cytochemistry; Flow cytometry; Hematological diagnosis; Immunohistochemistry; In situ hybridization; Karyotyping; Monoclonal antibodies

Indexed keywords

BONE MARROW BIOPSY; CHROMOSOME ANALYSIS; DIAGNOSTIC VALUE; ERYTHROCYTE STRUCTURE; FLOW CYTOMETRY; HEMATOLOGIC DISEASE; HUMAN; IMMUNOCYTOCHEMISTRY; LEUKEMIA; LEUKOCYTE STRUCTURE; MORPHOMETRICS; PATHOLOGIST; PATIENT MONITORING; PROGNOSIS; REVIEW; TREATMENT PLANNING;

BIOPSY, FINE-NEEDLE; BIOPSY, NEEDLE; BONE MARROW; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELLS; HUMANS; PATHOLOGY; STAINING AND LABELING;

EID: 70349553932     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20305     Document Type: Review

References (360)

1. Frisch B, Bartl R. Biopsy Interpretation of Bone and Bone Marrow. London: Arnold; 1999.
2. Gulati GL, Ashton JK, Hyun BH. Structure and function of the bone marrow and hematopoiesis. Hematol Oncol Clin North Am 1988;2:495-511. (Pubitemid 18276583)
3. Brown DC, Gatter KC. The bone marrow trephine biopsy: A review of normal histology. Histopathology 1993;22:411-422. (Pubitemid 23168581)
4. Frisch B, Bartl R. Evaluation of Bone and Bone Marrow Biopsies. Biopsy Interpretation of Bone and Bone Marrow. London: Arnold; 1999. p 12-37.
5. Travlos GS. Histopathology of bone marrow. Toxicol Pathol 2006;34:566-598.
6. Travlos GS. Normal structure, function, and histology of the bone marrow. Toxicol Pathol 2006;34:548-565. (Pubitemid 44652217)
7. Chanavaz M. Anatomy and histophysiology of the periosteum: Quantification of the periosteal blood supply to the adjacent bone with 85Sr and gamma spectrometry. J Oral Implantol 1995;21: 214-219.
8. Frisch B, Bartl R. Normal Bone Marrow. Biopsy Interpretation of Bone and Bone Marrow. London: Arnold; 1999. p 38-54.
9. Nardi NB, Alfonso ZZ. The hematopoietic stroma. Braz J Med Biol Res 1999;32:601-609.
10. Gordon MY. Physiology and function of the haemopoietic microenvironment. Br J Haematol 1994;86:241-243.
11. Mayani H, Guilbert LJ, Janowska-Wieczorek A. Biology of the hemopoietic microenvironment. Eur J Haematol 1992;49: 225-233.
12. Gimble JM, Robinson CE, Wu X, Kelly KA. The function of adipocytes in the bone marrow stroma: an update. Bone 1996;19:421-428. (Pubitemid 126745119)
13. Smith C. Hematopoietic stem cells and hematopoiesis. Cancer Control 2003;10:9-16.
14. Mauch P, Botnick LE, Hannon EC, Obbagy J, Hellman S. Decline in bone marrow proliferative capacity as a function of age. Blood 1982;60:245-252. (Pubitemid 12085946)
15. Fey MF. Normal and malignant hematopoiesis. Ann Oncol 2007;18:i9-i13.
16. Saharinen P. Signaling Through The Jak/Stat Pathway: Regulation of Tyrosine Kinase Activity. Helsinki: University of Helsinki; 2002. 102p.
17. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006;354(19):2034-2045.
18. Juul S, Felderhoff-Mueser U. Epo and other hematopoietic factors. Semin Fetal Neonatal Med 2007;12:250-258.
19. Nervi B, Link DC, DiPersio JF. Cytokines and hematopoietic stem cell mobilization. J Cell Biochem 2006;99:690-705. (Pubitemid 44521989)
20. Bessis M. Blood Smears Reinterpreted. Brecher G, Translator. Berlin: Springer; 1977. 270p.
21. Mel HC, Prenant M, Mohandas N. Reticulocyte motility and form: Studies on maturation and classification. Blood 1977;49: 1001-1001 (Pubitemid 8123867)
22. Castoldi GL, Beutler E. Erythrocytes. In: Zucker-Franklin D, Greaves MF, Grossi CE, Marmont AM, editors. Atlas of Blood Cells Function and Pathology, second edition. Philadelphia: Lea & Febiger; 1988. p 47-156.
23. Wojchowski DM, Menon MP, Sathyanarayana P, et al. Erythropoietin- dependent erythropoiesis: New insights and questions. Blood Cells Mol Dis 2006;36:232-238.
24. Richmond TD, Chohan M, Barber DL. Turning cells red: Signal transduction mediated by erythropoietin. Trends Cell Biol 2005;15:146-155. (Pubitemid 40332537)
25. Testa U. Apoptotic mechanisms in the control of erythropoiesis. Leukemia 2004;18:1176-1199.
26. Chasis JA. Erythroblastic islands: Specialized microenvironmental niches for erythropoiesis. Current Opin Hematol 2006;13: 137-141.
27. Chervenick PA, Zucker-Franklin D, Moore MAS. In vitro and in vivo hematopoiesis. In: Zucker-Franklin D, Greaves MF, Grossi CE, Marmont AM, editors. Atlas of Blood Cells Function and Pathology, second edition. Philadelphia: Lea & Febiger; 1988. p 3-27.
28. Faurschou M, Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect 2003;5: 1317-1327. (Pubitemid 37410245)
29. Lee WL, Harrison RE, Grinstein S. Phagocytosis by neutrophils. Microbes Infect 2003;5:1299-1306.
30. Roos D, van Bruggen R, Meischl C. Oxidative killing of microbes by neutrophils. Microbes Infect 2003;5:1307-1315.
31. Kostyak JC, Naik UP. Megakaryopoiesis: Transcriptional insights into megakaryocyte maturation. Front Biosci 2007;12: 2050-2062.
32. Kirito K, Kaushansky K. Transcriptional regulation of megakaryopoiesis: Thrombopoietin signaling and nuclear factors. Current Opin Hematol 2006;13:151-156. (Pubitemid 43755854)
33. Szalai G, LaRue AC, Watson DK. Molecular mechanisms of megakaryopoiesis. Cell Mol Life Sci 2006;63:2460-2476.
34. Vyas H, Krishnaswamy G. Paul Ehrlich's "Mastzellen"-From aniline dyes to DNA chip arrays: A historical review of developments in mast cell research. Methods Mol Biol 2006;315: 3-11.
35. Payne V, Kam PC. Mast cell tryptase: A review of its physiology and clinical significance. Anaesthesia 2004;59:695-703. (Pubitemid 38997011)
36. Muschler GF, Nitto H, Boehm CA, Easley KA. Age- and gender-related changes in the cellularity of human bone marrow and the prevalence of osteoblastic progenitors. J Orthop Res 2001;19: 117-125. (Pubitemid 32288644)
37. Hartsock RJ, Smith EB, Petty CS. Normal variations with aging of the amount of hematopoietic tissue in bone marrow from the anterior iliac crest. A study made from 177 cases of sudden death examined by necropsy. Am J Clin Pathol 1965;43:326-331.
38. Friebert SE, Shepardson LB, Shurin SB, Rosenthal GE, Rosenthal NS. Pediatric bone marrow cellularity: Are we expecting too much? J Pediatr Hematol Oncol 1998;20:439-443.
39. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128-1132. (Pubitemid 41323513)
40. Gruppo RA, Lampkin BC, Granger S. Bone marrow cellularity determination: Comparison of the biopsy, aspirate, and buffy coat. Blood 1977;49:29-31. (Pubitemid 8019481)
41. Fong TP, Okafor LA, Schmitz TH, Thomas W, Westerman MP. An evaluation of cellularity in various types of bone marrow specimens. Am J Clin Pathol 1979;72:812-816.
42. Wolff SN, Katzenstein AL, Phillips GL, Herzig GP. Aspiration does not influence interpretation of bone marrow biopsy cellularity. Am J Clin Pathol 1983;80:60-62.
43. Paul M, Chandy M, Pulimood R, Krishnaswami H. Cellularity of bone marrow - A comparison of trephine biopsies and aspirate smears. Indian J Pathol Microbiol 1989;32:186-189.
44. Ho-Yen DO, Slidders W. Bone marrow cellularity assessed by point-counting. J Clin Pathol 1978;31:753-756. (Pubitemid 9010945)
45. Kerndrup G, Pallesen G, Melsen F, Mosekilde L. Histomorphometrical determination of bone marrow cellularity in iliac crest biopsies. Scand J Haematol 1980;24:110-114.
46. Elmore SA. Enhanced histopathology of the bone marrow. Toxicol Pathol 2006;34:666-686.
47. Stuart-Smith SE, Hughes DA, Bain BJ. Are routine iron stains on bone marrow trephine biopsy specimens necessary? J Clin Pathol 2005;58:269-272.
48. Bain BJ. Bone marrow aspiration. J Clin Pathol 2001;54:657-663.
49. Buesche G, Georgii A, Kreipe HH. Diagnosis and quantification of bone marrow fibrosis are significantly biased by the prestaining processing of bone marrow biopsies. Histopathology 2006;48:133-148.
50. Bauermeister DE. Quantitation of bone marrow reticulin - A normal range. Am J Clin Pathol 1971;56:24-31.
51. Buesche G, Georgii A, Duensing A, Schmeil A, Schlue J, Kreipe HH. Evaluating the volume ratio of bone marrow affected by fibrosis: A parameter crucial for the prognostic significance of marrow fibrosis in chronic myeloid leukemia. Hum Pathol 2003;34:391-401. (Pubitemid 36535025)
52. Diebold J, Molina T, Camilleri-Broet S, Le Tourneau A, Audouin J. Bone marrow manifestations of infections and systemic diseases observed in bone marrow trephine biopsy review. Histopathology 2000;37:199-211. (Pubitemid 30695697)
53. Janssens AM, Offner FC, Van Hove WZ. Bone marrow necrosis. Cancer 2000;88:1769-1780.
54. Paydas S, Ergin M, Baslamisli F, et al. Bone marrow necrosis: Clinicopathologic analysis of 20 cases and review of the literature. Am J Hematol 2002;70:300-305. (Pubitemid 34810507)
55. Zhu AX, Niesvizky R, Hedrick E, Fata F, Filippa DA, Michaeli J. Extensive bone marrow necrosis associated with multiple myeloma. Leukemia 1999;13:2118-2120.
56. Kiraly 3rd JF, Wheby MS. Bone marrow necrosis. Am J Med 1976;60:361-368.
57. Norgard MJ, Carpenter Jr JT, Conrad ME. Bone marrow necrosis and degeneration. Arch Intern Med 1979;139: 905-911.
58. Maisel D, Lim JY, Pollock WJ, Yatani R, Liu PI. Bone marrow necrosis: An entity often overlooked. Ann Clin Lab Sci 1988;18:109-115. (Pubitemid 18115580)
59. Llewelyn MJ, Noursedeghi M, Dogan A, Edwards SG, Miller RF. Diagnostic utility of bone marrow sampling in HIVinfected patients since the advent of highly active antiretroviral therapy. Int J STD AIDS 2005;16:686-690. (Pubitemid 41527352)
60. Foucar K. Non-Hodgkin's lymphoma and Hodgkin's disease in bone marrow. In: Foucar K, editor. Bone Marrow Pathology. Chicago (IL): ASCP Press. p 343-375.
61. Dominis M, Pesut A, Borovecki A, Marusic-Vrsalovic M, Kusec R. Bone marrow lymphoid aggregates in malignant lymphomas. Croat Med J 2005;46:410-416. (Pubitemid 40686485)
62. Thiele J, Zirbes TK, Kvasnicka HM, Fischer R. Focal lymphoid aggregates (nodules) in bone marrow biopsies: Differentiation between benign hyperplasia and malignant lymphoma - A practical guideline. J Clin Pathol 1999;52:294-300. (Pubitemid 29161494)
63. Buhr T, Langer F, Schlue J, et al. Reliability of lymphoma classification in bone marrow trephines. Br J Haematol 2002;118: 470-476. (Pubitemid 34994651)
64. Torlakovic E, Torlakovic G, Brunning RD. Follicular pattern of bone marrow involvement by follicular lymphoma. Am J Clin Pathol 2002;118:780-786. (Pubitemid 37046324)
65. Thomas JSJ. The diagnosis of lymphoid infiltrates in the bone marrow trephine. Curr Diagn Pathol 2004;10:236-245. (Pubitemid 38859638)
66. Arber DA, George TI. Bone marrow biopsy involvement by non-Hodgkin's lymphoma: Frequency of lymphoma types, patterns, blood involvement, and discordance with other sites in 450 specimens. Am J Surg Pathol 2005;29:1549-1557.
67. Leong TY, Leong AS. How does antigen retrieval work? Adv Anat Pathol 2007;14:129-131.
68. Anagnostou D. Pitfalls in the pattern of bone marrow infiltration in lymphoproliferative disorders. Curr Diagn Pathol 2005;11: 170-179. (Pubitemid 40592075)
69. Campbell J, Seymour JF, Matthews J, Wolf M, Stone J, Juneja S. The prognostic impact of bone marrow involvement in patients with diffuse large cell lymphoma varies according to the degree of infiltration and presence of discordant marrow involvement. Eur J Haematol 2006;76:473-480.
70. Cotta CV, Konoplev S, Medeiros LJ, Bueso-Ramos CE. Metastatic tumors in bone marrow: Histopathology and advances in the biology of the tumor cells and bone marrow environment. Ann Diagn Pathol 2006;10:169-192. (Pubitemid 43765490)
71. Graf BL, Korte W, Schmid L, Schmid U, Cogliatti SB. Impact of aspirate smears and trephine biopsies in routine bone marrow diagnostics: A comparative study of 141 cases. Swiss Med Wkly 2005;135:151-159. (Pubitemid 40461246)
72. Janni W, Rack B, Lindemann K, Harbeck N. Detection of micrometastatic disease in bone marrow: Is it ready for prime time? Oncologist 2005;10:480-492.
73. Zach O, Lutz D. Tumor cell detection in peripheral blood and bone marrow. Curr Opin Oncol 2006;18:48-56. (Pubitemid 43740450)
74. Juneja SK, Wolf MM, Cooper IA. Value of bilateral bone marrow biopsy specimens in non-Hodgkin's lymphoma. J Clin Pathol 1990;43:630-632. (Pubitemid 20228919)
75. Luoni M, Declich P, De Paoli AP, et al. Bone marrow biopsy for the staging of non-Hodgkin's lymphoma: Bilateral or unilateral trephine biopsy? Tumori 1995;81:410-413.
76. Luoni M, Fava S, Declich P. Bone marrow biopsy for staging Hodgkin's lymphoma: The value of bilateral or unilateral trephine biopsy. J Clin Oncol 1996;14:682-683. (Pubitemid 26051040)
77. Menon NC, Buchanan JG. Bilateral trephine bone marrow biopsies in Hodgkin's and non-Hodgkin's lymphoma. Pathology 1979;11:53-57. (Pubitemid 9133913)
78. Valdes-Sanchez M, Nava-Ocampo AA, Palacios-Gonzalez RV, Perales-Arroyo A, Medina-Sanson A, Martinez-Avalos A. Diagnosis of bone marrow metastases in children with solid tumors and lymphomas. Aspiration, or unilateral or bilateral biopsy? Arch Med Res 2000;31:58-61.
79. Wang J, Weiss LM, Chang KL, et al. Diagnostic utility of bilateral bone marrow examination: Significance of morphologic and ancillary technique study in malignancy. Cancer 2002;94: 1522-1531. (Pubitemid 34212647)
80. Moid F, DePalma L. Comparison of relative value of bone marrow aspirates and bone marrow trephine biopsies in the diagnosis of solid tumor metastasis and Hodgkin lymphoma: Institutional experience and literature review. Arch Pathol Lab Med 2005;129:497-501. (Pubitemid 40471196)
81. Lau D, Mollnau H, Eiserich JP, et al. Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc Natl Acad Sci USA 2005;102:431-436. (Pubitemid 40116784)
82. Mufti GJ, Flandrin G, Schaefer H-E, Sandberg AA, Kanfer EJ. Appendix I. Selected Histological and Cytochemical Methods. An Atlas of Malignant Haematology Cytology, Histology, and Cytogenetics. Philadelphia: Lippincott-Raven Publishers; 1996. p 383-398.
83. Tanaka KR, Valentine WN, Fredricks RE. Diseases or clinical conditions associated with low leukocyte alkaline phosphatase. N Engl J Med 1960;262:912-918.
84. Koler RD, Seaman AJ, Osgood EE, Vanbellinghen P. Myeloproliferative diseases; Diagnostic value of the leukocyte alkaline phosphatase test. Am J Clin Pathol 1958;30: 295-301.
85. Kaplow LS. A histochemical procedure for localizing and evaluating leukocyte alkaline phosphatase activity in smears of blood and marrow. Blood 1955;10:1023-1029.
86. Wiltshaw E, Moloney WC. Histochemical and biochemical studies on leukocyte alkaline phosphatase activity. Blood 1955; 10:1120-1131.
87. Okamoto T, Okada M, Yamada S, et al. Flow-cytometric analysis of leukocyte alkaline phosphatase in myelodysplastic syndromes. Acta Haematol 1999;102:89-93. (Pubitemid 29469149)
88. Alamo AL, Melnick SJ. Clinical application of four and fivecolor flow cytometry lymphocyte subset immunophenotyping. Cytometry 2000;42:363-370.
89. Bleesing JJ, Fleisher TA. Immunophenotyping. Semin Hematol 2001;38:100-110.
90. Brown M, Wittwer C. Flow cytometry: Principles and clinical applications in hematology. Clin Chem 2000;46:1221-1229. (Pubitemid 30643294)
91. Regeczy N, Kormos L, Nahajevszky S, et al. Immunopheno-typing in acute leukaemias and its value in detection of residual disease. In: Mason D, Andre P, Bensussan A, et al., editors. Leucocyte Typing VII White Cell Differentiation Antigens. Proceedings of the Seventh International Workshop and Conference Held in Harrogate, United Kingdom. New York, NY: Oxford University Press; 2002.
92. Mason DY, Andre P, Bensussan A, et al. CD antigens 2001. Tissue Antigens 2001;58:425-430.
93. Zola H. Human leukocyte differentiation antigens as therapeutic targets: The CD molecules and CD antibodies. Expert Opin Biol Ther 2001;1:375-383. (Pubitemid 33768656)
94. Mason D, Andre P, Bensussan A, et al. CD antigens 2002. Blood 2002;99(10):3877-3880.
95. Mason D, Andre P, Bensussan A, et al., editors. Leucocyte Typing VII. White Cell Differentiation Antigens. Proceedings of the Seventh International Workshop and Conference held in Harrogate, United Kingdom. New York, NY: Oxford University Press; 2002.
96. Zola H, Swart B, Boumsell L, Mason DY. Human leucocyte differentiation antigen nomenclature: Update on CD nomenclature. Report of IUIS/WHO Subcommittee. J Immunol Methods 2003;275:1-8. (Pubitemid 36351537)
97. True LD, Liu AY. A challenge for the diagnostic immunohistopathologist. Adding the CD phenotypes to our diagnostic toolbox. Am J Clin Pathol 2003;120:13-15.
98. Institute NC. Protein Reviews on the Web; 2005.
99. Ichinohasama R. Immunophenotypic analysis in the diagnosis of malignant lymphoma. Nippon Rinsho 2000;58:591-597.
100. Chu PG, Chang KL, Arber DA, Weiss LM. Practical applications of immunohistochemistry in hematolymphoid neoplasms. Ann Diagn Pathol 1999;3:104-133.
101. Leers MP, Theunissen PH, Ramaekers FC, Schutte B, Nap M. Clonality assessment of lymphoproliferative disorders by multi-parameter flow cytometry of paraffin-embedded tissue: An additional diagnostic tool in surgical pathology. Human Pathol 2000;31:422-427. (Pubitemid 30262862)
102. Stetler-Stevenson M, Braylan RC. Flow cytometric analysis of lymphomas and lymphoproliferative disorders. Semin Hematol 2001;38:111-123. (Pubitemid 32319311)
103. Scheffold A, Kern F. Recent developments in flow cytometry. J Clin Immunol 2000;20:400-407.
104. Stewart CC. Multiparameter flow cytometry. J Immunoassay 2000;21:255-272.
105. Bakke AC. The principles of flow cytometry. Lab Med 2001;32:207-211.
106. Givan AL. Principles of flow cytometry: An overview. Methods Cell Biol 2001;63:19-50.
107. McCoy P. Flow cytometry. In: McClatchey KD, editor. Clinical Laboratory Medicine, second edition. Philadelphia: Lippincott, Williams, and Wilkins; 2002. p 1401-1425.
108. Mendelsohn ML. The attributes and applications of flow cytometry. Acta Pathol Microbiol Immunol Scand 1980;S274:15-27.
109. Chapman GV. Instrumentation for flow cytometry. J Immunol Methods 2000;243:3-12.
110. Kremer M, Quintanilla-Martinez L, Nahrig J, von Schilling C, Fend F. Immunohistochemistry in bone marrow pathology: A useful adjunct for morphologic diagnosis. Virchows Arch 2005;447:920-937. (Pubitemid 41719547)
111. Protein Reviews on the Web. CD MOLECULES. Human cell surface molecules recognized by the International Workshops on Human Leukocyte Differentiation Antigens.
112. Dahlke MH, Larsen SR, Rasko JE, Schlitt HJ. The biology of CD45 and its use as a therapeutic target. Leuk Lymphoma 2004;45:229-236. (Pubitemid 38181423)
113. Holmes N. CD45: All is not yet crystal clear. Immunology 2006;117:145-155.
114. Irie-Sasaki J, Sasaki T, Penninger JM. CD45 regulated signaling pathways. Curr Top Med Chem 2003;3:783-796.
115. Huntington ND, Tarlinton DM. CD45: Direct and indirect government of immune regulation. Immunol Lett 2004;94: 167-174.
116. Hermiston ML, Xu Z, Weiss A. CD45: A critical regulator of signaling thresholds in immune cells. Annu Rev Immunol 2003;21:107-137. (Pubitemid 37174528)
117. Shah VO, Civin CI, Loken MR. Flow cytometric analysis of human bone marrow. IV. Differential quantitative expression of T-200 common leukocyte antigen during normal hemopoiesis. J Immunol 1988;140:1861-1867.
118. Thomas ML, Lefrancois L. Differential expression of the leucocyte-common antigen family. Immunol Today 1988;9: 320-326. (Pubitemid 18229829)
119. Nicholson JK, Hubbard M, Jones BM. Use of CD45 fluorescence and side-scatter characteristics for gating lymphocytes when using the whole blood lysis procedure and flow cytometry. Cytometry 1996;26:16-21.
120. Stelzer GT, Shults KE, Loken MR. CD45 gating for routine flow cytometric analysis of human bone marrow specimens. Ann N Y Acad Sci 1993;677:265-280.
121. Glencross D, Scott LE, Jani IV, Barnett D, Janossy G. CD45- assisted Pan Leucogating for accurate, cost-effective dual-platform CD41 T-cell enumeration. Cytometry 2002;50:69-77.
122. Vial JP, Lacombe F. Immunophenotyping of acute leukemia: Utility of CD45 for blast cell identification. Methods Cell Biol 2001;64:343-358. (Pubitemid 33798420)
123. Wood B. Multicolor immunophenotyping: Human immune system hematopoiesis. Methods Cell Biol 2004;75:559-576. (Pubitemid 39752539)
124. Paietta E. Detection of terminal transferase in leukemia. Methods Mol Biol 1998;91:25-36.
125. Kaleem Z, Crawford E, Pathan MH, et al. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. Arch Pathol Lab Med 2003;127:42-48.
126. Rimsza LM, Larson RS, Winter SS, et al. Benign hematogonerich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features. Am J Clin Pathol 2000;114:66-75.
127. Liu L, McGavran L, Lovell MA, et al. Nonpositive terminal deoxynucleotidyl transferase in pediatric precursor B-lymphoblastic leukemia. Am J Clin Pathol 2004;121:810-815. (Pubitemid 38669274)
128. Walker J, Green JM. Structural requirements for CD43 function. J Immunol 1999;162:4109-4114.
129. Contos MJ, Kornstein MJ, Innes DJ, Ben-Ezra J. The utility of CD20 and CD43 in subclassification of low-grade B-cell lymphoma on paraffin sections. Mod Pathol 1992;5: 631-633.
130. Segal GH, Stoler MH, Tubbs RR. The "CD43 only" phenotype. An aberrant, nonspecific immunophenotype requiring comprehensive analysis for lineage resolution. Am J Clin Pathol 1992;97: 861-865.
131. Jung G, Eisenmann JC, Thiebault S, Henon P. Cell surface CD43 determination improves diagnostic precision in late B-cell diseases. Br J Haematol 2003;120:496-499. (Pubitemid 36241510)
132. Blumberg RS, Gerdes D, Chott A, Porcelli SA, Balk SP. Structure and function of the CD1 family of MHC-like cell surface proteins. Immunol Rev 1995;147:5-29.
133. Hava DL, Brigl M, van den Elzen P, Zajonc DM, Wilson IA, Brenner MB. CD1 assembly and the formation of CD1-antigen complexes. Curr Opin Immunol 2005;17:88-94. (Pubitemid 40094019)
134. Dougan SK, Kaser A, Blumberg RS. CD1 expression on antigen-presenting cells. Curr Topics Microbiol Immunol 2007;314: 113-141.
135. Zajonc DM, Wilson IA. Architecture of CD1 proteins. Curr Topics Microbiol Immunol 2007;314:27-50.
136. Young DC, Moody DB. T-cell recognition of glycolipids presented by CD1 proteins. Glycobiology 2006;16:103R-112R.
137. Gumperz JE. The ins and outs of CD1 molecules: Bringing lipids under immunological surveillance. Traffic 2006;7:2-13.
138. Salamone MC, Roisman FR, Santiago J, Satz ML, Fainboim L. Analysis of CD1 molecules on haematological malignancies of myeloid and lymphoid origin. I. Cell surface antigen expression. Dis Markers 1990;8:265-274.
139. Salamone MC, Roisman FR, Morelli AE, Noli MI, Fainboim L. Analysis of CD1 molecules on haematological malignancies of myeloid and lymphoid origin. II. Intracellular detection of CD1 antigens. Dis Markers 1990;8:275-281.
140. -) phenotype. Am J Hematol 1992;40:98-102.
141. Yang JJ, Ye Y, Carroll A, Yang W, Lee HW. Structural biology of the cell adhesion protein CD2: Alternatively folded states and structure-function relation. Curr Protein Pept Sci 2001;2: 1-17. (Pubitemid 32409756)
142. Bromberg JS. The biology of CD2: Adhesion, transmembrane signal, and regulatory receptor of immunity. J Surg Res 1993;54:258-267.
143. McNerney ME, Kumar V. The CD2 family of natural killer cell receptors. Curr Topics Microbiol Immunol 2006;298:91-120.
144. Jamal S, Picker LJ, Aquino DB, McKenna RW, Dawson DB, Kroft SH. Immunophenotypic analysis of peripheral T-cell neoplasms. A multiparameter flow cytometric approach. Am J Clin Pathol 2001;116:512-526. (Pubitemid 34450285)
145. Lin P, Hao S, Medeiros LJ, et al. Expression of CD2 in acute promyelocytic leukemia correlates with short form of PML-RARalpha transcripts and poorer prognosis. Am J Clin Pathol 2004;121:402-407. (Pubitemid 38298174)
146. Della Porta MG. CD34 and CD2 expression in acute promyelocytic leukemia. Haematologica 2006;91:289C.
147. Kuhns MS, Davis MM, Garcia KC. Deconstructing the form and function of the TCR/CD3 complex. Immunity 2006; 24:133-139. (Pubitemid 43214583)
148. Minguet S, Swamy M, Alarcon B, Luescher IF, Schamel WW. Full activation of the T cell receptor requires both clustering and conformational changes at CD3. Immunity 2007;26:43-54. (Pubitemid 46109342)
149. + T-cell enumeration. Cytometry 1997;30:157-165.
150. Nicholson JK. Immunophenotyping specimens from HIV-infected persons: Laboratory guidelines from the Centers for Disease Control and Prevention. Cytometry 1994;18:55-59.
151. Leahy DJ. A structural view of CD4 and CD8. FASEB J 1995;9:17-25.
152. Janeway Jr CA. The role of CD4 in T-cell activation: Accessory molecule or co-receptor? Immunol Today 1989;10:234-238.
153. - immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. J Am Acad Dermatol 1996;35:404-410.
154. -) T cells compose the dominant T-cell clone in the peripheral blood of patients with Sezary syndrome. J Am Acad Dermatol 2001;44: 456-461.
155. Sarrias MR, Gronlund J, Padilla O, Madsen J, Holmskov U, Lozano F. The Scavenger receptor cysteine-rich (SRCR) domain: An ancient and highly conserved protein module of the innate immune system. Crit Rev Immunol 2004;24:1-37. (Pubitemid 39655010)
156. + B-cell. Int J Biochem Cell Biol 2004;36:2105-2111.
157. Sempowski GD, Lee DM, Kaufman RE, Haynes BF. Structure and function of the CD7 molecule. Crit Rev Immunol 1999;19: 331-348.
158. Chan AS, Reynolds PJ, Shimizu Y. Tyrosine kinase activity associated with the CD7 antigen: Correlation with regulation of T cell integrin function. Eur J Immunol 1994;24:2602-2608. (Pubitemid 24342172)
159. Barcena A, Muench MO, Roncarolo MG, Spits H. Tracing the expression of CD7 and other antigens during T- and myeloid-cell differentiation in the human fetal liver and thymus. Leuk Lymphoma 1995;17:1-11.
160. Pagnucco G, Vanelli L, Gervasi F. Multidimensional flow cytometry immunophenotyping of hematologic malignancy. Ann N Y Acad Sci 2002;963:313-321. (Pubitemid 34721724)
161. Tiftik N, Bolaman Z, Batun S, et al. The importance of CD7 and CD56 antigens in acute leukaemias. Int J Clin Pract 2004;58: 149-152. (Pubitemid 38425745)
162. Murphy M, Fullen D, Carlson JA. Low CD7 expression in benign and malignant cutaneous lymphocytic infiltrates: Experience with an antibody reactive with paraffin-embedded tissue. Am J Dermatopathol 2002;24:6-16. (Pubitemid 34121780)
163. Chang H, Yeung J, Brandwein J, Yi QL. CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype. Leuk Res 2007;31:157-162. (Pubitemid 44854199)
164. Singer A, Bosselut R. CD4/CD8 coreceptors in thymocyte development, selection, and lineage commitment: Analysis of the CD4/CD8 lineage decision. Adv Immunol 2004;83:91-131. (Pubitemid 38657638)
165. Zamoyska R. CD4 and CD8: Modulators of T-cell receptor recognition of antigen and of immune responses? Curr Opin Immunol 1998;10:82-87.
166. Devine L, Kavathas PB. Molecular analysis of protein interactions mediating the function of the cell surface protein CD8. Immunol Res 1999;19:201-210. (Pubitemid 29401377)
167. Gorczyca W, Weisberger J, Liu Z, et al. An approach to diagnosis of T-cell lymphoproliferative disorders by flow cytometry. Cytometry 2002;50:177-190.
168. van Sorge NM, van der Pol WL, van de Winkel JG. Fcgamma R polymorphisms: Implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003;61:189-202.
169. Cohen-Solal JF, Cassard L, Fridman WH, Sautes-Fridman C. Fc gamma receptors. Immunol Lett 2004;92:199-205.
170. Perussia B, Trinchieri G, Jackson A, et al. The Fc receptor for IgG on human natural killer cells: Phenotypic, functional, and comparative studies with monoclonal antibodies. J Immunol 1984;133:180-189. (Pubitemid 14077899)
171. Looney RJ, Abraham GN, Anderson CL. Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol 1986;136:1641-1647.
172. Fleit HB. Monoclonal antibodies to human neutrophil Fc gamma RIII (CD16) identify polypeptide epitopes. Clin Immunol Immunopathol 1991;59:222-235.
173. Groh V, Porcelli S, Fabbi M, et al. Human lymphocytes bearing T cell receptor gamma/delta are phenotypically diverse and evenly distributed throughout the lymphoid system. J Exp Med 1989;169:1277-1294. (Pubitemid 19104962)
174. Schubert J, Lanier LL, Schmidt RE. Cluster report: CD56. In: Knapp W, Dörken B, Rieber EP, et al., editors. Leucocyte Typing IV White Cell Differentiation Antigens. Oxford: Oxford University Press; 1989. p 699-702.
175. Umezawa Y, Kuge S, Kikyo N, et al. Identity of brain-associated small cell lung cancer antigen and the CD56 (NKH-1/Leu-19) leukocyte differentiation antigen and the neural cell adhesion molecule. Jpn J Clin Oncol 1991;21:251-255.
176. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001;22:633-640.
177. Lee JJ, Chung IJ, Yang DH, et al. Clinical significance of CD56 expression in patients with acute myeloid leukemia. Leuk Lymphoma 2002;43:1897-1899.
178. Ferrara F, Morabito F, Martino B, et al. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous alltrans-retinoic acid and chemotherapy. J Clin Oncol 2000;18: 1295-1300. (Pubitemid 30159848)
179. Yang DH, Lee JJ, Mun YC, et al. Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation. Am J Hematol 2007;82:1-5.
180. Ely SA, Knowles DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am J Pathol 2002;160:1293-1299.
181. Schubert J, Lanier L, Schmidt RE. Cluster report: CD57. In: Knapp W, Dörken B, Rieber EP, et al., editors. Leucocyte Typing IV White Cell Differentiation Antigens. Oxford: Oxford University Press; 1989. p 711-714.
182. van den Berg LH, Sadiq SA, Thomas FP, Latov N. Characterization of HNK-1 bearing glycoproteins in human peripheral nerve myelin. J Neurosci Res 1990;25:295-299. (Pubitemid 20136578)
183. Evans TG, Kallas EG, Luque AE, Menegus M, McNair C, Looney RJ. Expansion of the CD57 subset of CD8 T cells in HIV-1 infection is related to CMV serostatus. Aids 1999;13: 1139-1141. (Pubitemid 29361406)
184. - CD81 T-cell population. Immunology 1999;98:443-449.
185. + cell population in normal healthy individuals and matched unrelated T-cell-depleted bone marrow transplant recipients. Br J Haematol 2000;110:315-321.
186. Pulford K, Mason D. CD246 (ALK) cluster report. In: Mason D, Andre P, Bensussan A, et al., editors. Leucocyte Typing VII White Cell Differentiation Antigens. Proceedings of the Seventh International Workshop and Conference held in Harrogate, United Kingdom. New York, NY: Oxford University Press; 2002.
187. Morris SW, Naeve C, Mathew P, et al. ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK). Oncogene 1997;14:2175-2188.
188. Epstein J. Alk-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol 2005;29:839.
189. Jaffe ES. Anaplastic large cell lymphoma: The shifting sands of diagnostic hematopathology. Mod Pathol 2001;14:219-228. (Pubitemid 32246828)
190. Gascoyne RD, Lamant L, Martin-Subero JI, et al. ALK-positive diffuse large B-cell lymphoma is associated with Clathrin- ALK rearrangements: Report of 6 cases. Blood 2003;102: 2568-2573. (Pubitemid 37193597)
191. Bubala H, Maldyk J, Wlodarska I, Sonta-Jakimczyk D, Szczepanski T. ALK-positive diffuse large B-cell lymphoma. Pediatr Blood Cancer 2006;46:649-653.
192. LeBien TW, McCormack RT. The common acute lymphoblastic leukemia antigen (CD10) - Emancipation from a functional enigma. Blood 1989;73:625-635. (Pubitemid 19069159)
193. Turner AJ, Isaac RE, Coates D. The neprilysin (NEP) family of zinc metalloendopeptidases: Genomics and function. Bioessays 2001;23:261-269. (Pubitemid 32192145)
194. Bene MC, Faure GC. CD10 in acute leukemias. GEIL (Groupe d'Etude Immunologique des Leucemies). Haematologica 1997; 82:205-210.
195. Xu Y, McKenna RW, Kroft SH. Comparison of multiparameter flow cytometry with cluster analysis and immunohistochemistry for the detection of CD10 in diffuse large B-Cell lymphomas. Mod Pathol 2002;15:413-419. (Pubitemid 34326949)
196. Xu Y, McKenna RW, Kroft SH. Assessment of CD10 in the diagnosis of small B-cell lymphomas: A multiparameter flow cytometric study. Am J Clin Pathol 2002;117:291-300. (Pubitemid 34823671)
197. Riley RS, Massey D, Jackson-Cook C, Idowu M, Romagnoli G. Immunophenotypic analysis of acute lymphocytic leukemia. Hematol Oncol Clin North Am 2002;16:245-299. (Pubitemid 34663651)
198. Attarbaschi A, Mann G, Konig M, et al. Mixed lineage leukemiarearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity. Clin Cancer Res 2006;12:2988-2994. (Pubitemid 43837342)
199. Hirose J, Kouro T, Igarashi H, Yokota T, Sakaguchi N, Kincade PW. A developing picture of lymphopoiesis in bone marrow. Immunol Rev 2002;189:28-40. (Pubitemid 35448941)
200. Bertram HC, Check IJ, Milano MA. Immunophenotyping large B-cell lymphomas. Flow cytometric pitfalls and pathologic correlation. Am J Clin Pathol 2001;116:191-203.
201. Robak T. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk Lymphoma 2004;45:205-219. (Pubitemid 38181421)
202. Tedder TF, Disteche CM, Louie E, et al. The gene that encodes the human CD20 (B1) differentiation antigen is located on chromosome 11 near the t(11;14)(q13;q32) translocation site. J Immunol 1989;142:2555-2559.
203. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-174.
204. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: History and mechanism of action. Am J Transplant 2006; 6:859-866. (Pubitemid 44356635)
205. Nadler LM, Stashenko P, Hardy R, van Agthoven A, Terhorst C, Schlossman SF. Characterization of a human B cell-specific antigen (B2) distinct from B1. J Immunol 1981;126:1941-1947.
206. Iida K, Nadler L, Nussenzweig V. Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med 1983;158:1021-1033.
207. Tessier J, Cuvillier A, Glaudet F, Khamlichi AA. Internalization and molecular interactions of human CD21 receptor. Mol Immunol 2007;44:2415-2425. (Pubitemid 46097109)
208. Dörken B, Möller P, Pezzutto A, Schwartz-Albeiz R, Moldenhauer G. B-cell antigens: CD21. In: Knapp W, Dörken B, Rieber EP, et al., editors. Leucocyte Typing IV White Cell Differentiation Antigens. Oxford: Oxford University Press; 1989. p 58-60.
209. Cooper NR, Bradt BM, Rhim JS, Nemerow GR. CR2 complement receptor. J Invest Dermatol 1990;94:112S-117S.
210. Schuurman HJ, Huppes W, Verdonck LF, Van Baarlen J, Van Unnik JA. Immunophenotyping of non-Hodgkin's lymphoma. Correlation with relapse-free survival. Am J Pathol 1988;131: 102-111. (Pubitemid 18106924)
211. Echeverri C, Fisher S, King D, Craig FE. Immunophenotypic variability of B-cell non-Hodgkin lymphoma: A retrospective study of cases analyzed by flow cytometry. Am J Clin Pathol 2002;117:615-620. (Pubitemid 34823692)
212. Shiozawa E, Yamochi-Onizuka T, Yamochi T, et al. Disappearance of CD21-positive follicular dendritic cells preceding the transformation of follicular lymphoma: Immunohistological study of the transformation using CD21, p53, Ki-67, and P-glycoprotein. Pathol Res Pract 2003;199:293-302.
213. Otsuka M, Yakushijin Y, Hamada M, Hato T, Yasukawa M, Fujita S. Role of CD21 antigen in diffuse large B-cell lymphoma and its clinical significance. Br J Haematol 2004;127: 416-424. (Pubitemid 39536593)
214. Deaglio S, Vaisitti T, Bergui L, et al. CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. Blood 2005;105:3042-3050. (Pubitemid 40504319)
215. Partida-Sanchez S, Rivero-Nava L, Shi G, Lund FE. CD38: An ecto-enzyme at the crossroads of innate and adaptive immune responses. Adv Exp Med Biol 2007;590:171-183.
216. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol 2004;121:482-488. (Pubitemid 38392955)
217. Mainou-Fowler T, Dignum HM, Proctor SJ, Summerfield GP. The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL). Leuk Lymphoma 2004;45:455-462. (Pubitemid 38196027)
218. Thornton PD, Fernandez C, Giustolisi GM, et al. CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. Hematol J 2004;5:145-151. (Pubitemid 38519264)
219. Hus I, Podhorecka M, Bojarska-Junak A, et al. The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol 2006;17:683-690.
220. Ng AP, Wei A, Bhurani D, Chapple P, Feleppa F, Juneja S. The sensitivity of CD138 immunostaining of bone marrow trephine specimens for quantifying marrow involvement in MGUS and myeloma, including samples with a low percentage of plasma cells. Haematologica 2006;91:972-975. (Pubitemid 44023155)
221. Sun WP, Wang FM, Xie F, et al. A novel anti-human Syndecan-1 (CD138) monoclonal antibody 4B3: Characterization and application. Cell Mol Immunol 2007;4:209-214.
222. Ekholm SV, Reed SI. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 2000;12: 676-684.
223. McGowan CH. Regulation of the eukaryotic cell cycle. Prog Cell Cycle Res 2003;5:1-4.
224. Tashiro E, Tsuchiya A, Imoto M. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression. Cancer Sci 2007;98:629-635. (Pubitemid 46563437)
225. Lesage D, Troussard X, Sola B. The enigmatic role of cyclin D1 in multiple myeloma. Int J Cancer 2005;115:171-176. (Pubitemid 40586724)
226. Liu H, Wang J, Epner EM. Cyclin D1 activation in B-cell malignancy: Association with changes in histone acetylation, DNA methylation, and RNA polymerase II binding to both promoter and distal sequences. Blood 2004;104:2505-2513.
227. Oertel J, Kingreen D, Busemann C, Stein H, Dorken B. Morphologic diagnosis of leukaemic B-lymphoproliferative disorders and the role of cyclin D1 expression. J Cancer Res Clin Oncol 2002;128:182-188. (Pubitemid 34280375)
228. Vasef MA, Medeiros LJ, Koo C, McCourty A, Brynes RK. Cyclin D1 immunohistochemical staining is useful in distinguishing mantle cell lymphoma from other low-grade B-cell neoplasms in bone marrow. Am J Clin Pathol 1997;108:302-307. (Pubitemid 27371649)
229. Yatabe Y, Suzuki R, Matsuno Y, et al. Morphological spectrum of cyclin D1-positive mantle cell lymphoma: Study of 168 cases. Pathol Int 2001;51:747-761. (Pubitemid 33078393)
230. Droin NM, Green DR. Role of Bcl-2 family members in immunity and disease. Biochim Biophys Acta 2004;1644:179-188.
231. Walensky LD. BCL-2 in the crosshairs: Tipping the balance of life and death. Cell Death Differ 2006;13:1339-1350.
232. Cook JR, Craig FE, Swerdlow SH. bcl-2 expression by multicolor flow cytometric analysis assists in the diagnosis of follicular lymphoma in lymph node and bone marrow. Am J Clin Pathol 2003;119:145-151.
233. Pasqualucci L, Bereschenko O, Niu H, et al. Molecular pathogenesis of non-Hodgkin's lymphoma: The role of Bcl-6. Leuk Lymphoma 2003;44:S5-S12. (Pubitemid 38196057)
234. Ranuncolo SM, Polo JM, Dierov J, et al. Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nat Immunol 2007;8:705-714. (Pubitemid 46965346)
235. Torlakovic E, Torlakovic G, Nguyen PL, Brunning RD, Delabie J. The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: A novel pan pre-B and B-cell marker. Am J Surg Pathol 2002;26:1343-1350.
236. Foss HD, Reusch R, Demel G, et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 1999;94:3108-3113. (Pubitemid 29512717)
237. Zhang X, Lin Z, Kim I. Pax5 expression in non-Hodgkin's lymphomas and acute leukemias. J Korean Med Sci 2003;18: 804-808. (Pubitemid 38072929)
238. Browne P, Petrosyan K, Hernandez A, Chan JA. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol 2003;120:767-777. (Pubitemid 37339686)
239. Springer TA, Dustin ML, Kishimoto TK, Marlin SD. The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: Cell adhesion receptors of the immune system. Annu Rev Immunol 1987;5:223-252.
240. Mazzone A, Ricevuti G. Leukocyte CD11/CD18 integrins: Biological and clinical relevance. Haematologica 1995;80: 161-175.
241. Graf M, Reif S, Kroll T, Hecht K, Nuessler V, Schmetzer H. Expression of MAC-1 (CD11b) in acute myeloid leukemia (AML) is associated with an unfavorable prognosis. Am J Hematol 2006;81:227-235.
242. Robbins BA, Ellison DJ, Spinosa JC, et al. Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood 1993;82:1277-1287.
243. Nicolaou F, Teodoridis JM, Park H, et al. CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes ras and junD. Blood 2003;101: 4033-4041. (Pubitemid 36857883)
244. Cowburn AS, Sobolewski A, Reed BJ, et al. Aminopeptidase N (CD13) regulates tumor necrosis factor-alpha-induced apoptosis in human neutrophils. J Biol Chem 2006;281:12458-12467. (Pubitemid 43855332)
245. Mina-Osorio P, Shapiro LH, Ortega E. CD13 in cell adhesion: Aminopeptidase N (CD13) mediates homotypic aggregation of monocytic cells. J Leukoc Biol 2006;79:719-730. (Pubitemid 44835604)
246. Reinhold D, Biton A, Pieper S, et al. Dipeptidyl peptidase IV (DP IV, CD26) and aminopeptidase N (APN, CD13) as regulators of T cell function and targets of immunotherapy in CNS inflammation. Int Immunopharmacol 2006;6:1935-1942.
247. Gadd S. Cluster report: CD13. In: Knapp W, Dörken B, Rieber EP, et al., editors. Leucocyte Typing IV White Cell Differentiation Antigens. Oxford: Oxford University Press; 1989. p 782-784.
248. Orfao A, Chillon MC, Bortoluci AM, et al. The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements. Haematologica 1999; 84:405-412.
249. Kotylo PK, Seo IS, Smith FO, et al. Flow cytometric immunophenotypic characterization of pediatric and adult minimally differentiated acute myeloid leukemia (AML-M0). Am J Clin Pathol 2000;113:193-200.
250. Kraguljac N, Marisavljevic D, Jankovic G, et al. Characterization of CD13 and CD33 surface antigen-negative acute myeloid leukemia. Am J Clin Pathol 2000;114:29-34. (Pubitemid 34453182)
251. Ferrero E, Hsieh CL, Francke U, Goyert SM. CD14 is a member of the family of leucine-rich proteins and is encoded by a gene syntenic with multiple receptor genes. J Immunol 1990;145: 331-336. (Pubitemid 20217420)
252. Haziot A, Chen S, Ferrero E, Low MG, Silber R, Goyert SM. The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol 1988;141:547-552. (Pubitemid 18210257)
253. Goyert SM, Ferrero E, Rettig WJ, Yenamandra AK, Obata F, Le Beau MM. The CD14 monocyte differentiation antigen maps to a region encoding growth factors and receptors. Science 1988;239:497-500. (Pubitemid 18084313)
254. Fujihara M, Muroi M, Tanamoto K, Suzuki T, Azuma H, Ikeda H. Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: Roles of the receptor complex. Pharmacol Ther 2003;100:171-194. (Pubitemid 37377912)
255. Finberg RW, Kurt-Jones EA. CD14: Chaperone or matchmaker? Immunity 2006;24:127-129.
256. Goyert SM, Ferrero EM, Seremetis SV, Winchester RJ, Silver J, Mattison AC. Biochemistry and expression of myelomonocytic antigens. J Immunol 1986;137:3909-3914.
257. Ziegler-Heitbrock HW, Pechumer H, Petersmann I, et al. CD14 is expressed and functional in human B cells. Eur J Immunol 1994;24:1937-1940. (Pubitemid 24237572)
258. Skubitz KM, Snook 2nd RW. Monoclonal antibodies that recognize lacto-N-fucopentaose III (CD15) react with the adhesion-promoting glycoprotein family (LFA-1/HMac-1/gp 150,95) and CR1 on human neutrophils. J Immunol 1987;139: 1631-1639.
259. Warren HS, Altin JG, Waldron JC, Kinnear BF, Parish CR. A carbohydrate structure associated with CD15 (Lewis x) on myeloid cells is a novel ligand for human CD2. J Immunol 1996;156:2866-2873.
260. Schwartz-Albiez B. CD15 workshop report. In: Mason D, Andre P, Bensussan A, et al., editors. Leucocyte Typing VII White Cell Differentiation Antigens. Proceedings of the Seventh International Workshop and Conference held in Harrogate, United Kingdom. New York, NY: Oxford University Press; 2002. p 178-179.
261. Hakomori S. Le(X) and related structures as adhesion molecules. Histochem J 1992;24:771-776.
262. Peiper SC, Ashmun RA, Look AT. Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen. Blood 1988;72: 314-321.
263. Ulyanova T, Blasioli J, Woodford-Thomas TA, Thomas ML. The sialoadhesin CD33 is a myeloid-specific inhibitory receptor. Eur J Immunol 1999;29:3440-3449. (Pubitemid 29527791)
264. Wellhausen SR, Peiper SC. CD33: Biochemical and biological characterization and evaluation of clinical relevance. J Biol Regul Homeost Agents 2002;16:139-143.
265. Paul SP, Taylor LS, Stansbury EK, McVicar DW. Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 2000;96:483-490.
266. Mingari MC, Vitale C, Romagnani C, Falco M, Moretta L. Regulation of myeloid cell proliferation and survival by p75/AIRM1 and CD33 surface receptors. Adv Exp Med Biol 2001;495:55-61. (Pubitemid 34106917)
267. Avril T, Attrill H, Zhang J, Raper A, Crocker PR. Negative regulation of leucocyte functions by CD33-related siglecs. Biochem Soc Trans 2006;34:1024-1027. (Pubitemid 46768981)
268. Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: Progress in understanding cytotoxicity and potential mechanisms of drug resistance. Leukemia 2005;19:176-182.
269. Nakase K, Kita K, Shiku H, et al. Myeloid antigen, CD13, CD14, and/or CD33 expression is restricted to certain lymphoid neoplasms. Am J Clin Pathol 1996;105:761-768. (Pubitemid 26178723)
270. Sutherland DR, Watt SM, Dowden G, et al. Structural and partial amino acid sequence analysis of the human hemopoietic progenitor cell antigen CD34. Leukemia 1988;2:793-803. (Pubitemid 19017105)
271. Tenen DG, Satterthwaite AB, Borson R, Simmons D, Eddy RL, Shows TB. Chromosome 1 localization of the gene for CD34, a surface antigen of human stem cells. Cytogenet Cell Genet 1990;53:55-57. (Pubitemid 20113430)
272. Krause DS, Fackler MJ, Civin CI, May WS. CD34: Structure, biology, and clinical utility. Blood 1996;87:1-13.
273. Fackler MJ, Civin CI, Sutherland DR, Baker MA, May WS. Activated protein kinase C directly phosphorylates the CD34 antigen on hematopoietic cells. J Biol Chem 1990;265: 11056-11061. (Pubitemid 20200103)
274. Furness SG, McNagny K. Beyond mere markers: Functions for CD34 family of sialomucins in hematopoiesis. Immunol Res 2006;34:13-32. (Pubitemid 43780374)
275. Fina L, Molgaard HV, Robertson D, et al. Expression of the CD34 gene in vascular endothelial cells. Blood 1990;75: 2417-2426. (Pubitemid 20202322)
276. Sowala H, Wunder E, Henon P. Purification and characterisation of the CD341 hematopoietic precursor cell population by flow cytometry. Bone Marrow Transplant 1990;5:9-10. (Pubitemid 20118141)
277. Barton Furness SG, McNagny K. Beyond mere markers: Functions for CD34 family of sialomucins in hematopoiesis. Immunol Res 2006;34:13-32. (Pubitemid 43780374)
278. Civin CI, Trischmann TM, Fackler MJ, et al. Report on the CD34 cluster. In: Knapp W, Dörken B, Rieber EP, et al., editors. Leucocyte Typing IV White Cell Differentiation Antigens. Oxford: Oxford University Press; 1989. p 818-825.
279. Satterthwaite AB, Borson R, Tenen DG. Regulation of the gene for CD34, a human hematopoietic stem cell antigen, in KG-1 cells. Blood 1990;75:2299-2304. (Pubitemid 20202306)
280. + hematopoietic stem and progenitor cells in leukapheresis product and bone marrow for clinical transplantation: A comparison of three methods. Folia Histochem Cytobiol 2006;44:53-60.
281. Borowitz MJ, Gockerman JP, Moore JO, et al. Clinicopathologic and cytogenic features of CD34 (My 10)-positive acute nonlymphocytic leukemia. Am J Clin Pathol 1989;91:265-270. (Pubitemid 19074534)
282. Borowitz MJ, Shuster JJ, Civin CI, et al. Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia: A Pediatric Oncology Group study. J Clin Oncol 1990;8:1389-1398. (Pubitemid 20252311)
283. Majdic O. B-cell antigens: CD64. In: Knapp W, Dörken B, Rieber EP, et al., editors. Leucocyte Typing IV White Cell Differentiation Antigens. Oxford: Oxford University Press; 1989. p 835-836.
284. Krasinskas AM, Wasik MA, Kamoun M, Schretzenmair R, Moore J, Salhany KE. The usefulness of CD64, other monocyte-associated antigens, and CD45 gating in the subclassification of acute myeloid leukemias with monocytic differentiation. Am J Clin Pathol 1998;110:797-805. (Pubitemid 28541557)
285. Stockinger H. B-cell antigens: CD68. In: Knapp W, Dörken B, Rieber EP, et al., editors. Leucocyte Typing IV White Cell Differentiation Antigens. Oxford: Oxford University Press; 1989. p 841-843.
286. Binder SW, Said JW, Shintaku IP, Pinkus GS. A histiocytespecific marker in the diagnosis of malignant fibrous histiocytoma. Use of monoclonal antibody KP-1 (CD68). Am J Clin Pathol 1992;97:759-763.
287. Strobl H, Scheinecker C, Csmarits B, Majdic O, Knapp W. Flow cytometric analysis of intracellular CD68 molecule expression in normal and malignant haemopoiesis. Br J Haematol 1995;90: 774-782.
288. Beranek JT. CD68 is not a macrophage-specific antigen. Ann Rheum Dis 2005;64:342-343; author reply 343-344.
289. Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol 1994;55:1-96. (Pubitemid 2026071)
290. Ashman LK. The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999;31:1037-1051.
291. Dunphy CH, Polski JM, Evans HL, Gardner LJ. Evaluation of bone marrow specimens with acute myelogenous leukemia for CD34, CD15, CD117, and myeloperoxidase. Arch Pathol Lab Med 2001;125:1063-1069.
292. Newell JO, Cessna MH, Greenwood J, Hartung L, Bahler DW. Importance of CD117 in the evaluation of acute leukemias by flow cytometry. Cytometry B Clin Cytom 2003;52: 40-43. (Pubitemid 38297643)
293. Naresh KN, Lampert IA. CD117 Expression as an aid to identify immature myeloid cells and foci of ALIP in bone marrow trephines. Am J Hematol 2006;81:79.
294. Fullard JF. The role of the platelet glycoprotein IIb/IIIa in thrombosis and haemostasis. Curr Pharm Des 2004;10: 1567-1576. (Pubitemid 38559768)
295. von dem Borne AEG, Modderman PW. Cluster report: CD41. In: Knapp W, Dörken B, Rieber EP, et al., editors. Leucocyte Typing IV White Cell Differentiation Antigens. Oxford: Oxford University Press; 1989. p 997-999.
296. van Pampus EC, Denkers IA, van Geel BJ, et al. Expression of adhesion antigens of human bone marrow megakaryocytes, circulating megakaryocytes and blood platelets. Eur J Haematol 1992;49:122-127.
297. Debili N, Robin C, Schiavon V, et al. Different expression of CD41 on human lymphoid and myeloid progenitors from adults and neonates. Blood 2001;97:2023-2030. (Pubitemid 32239082)
298. Clemetson KJ, Clemetson JM. Molecular abnormalities in Glanzmann's thrombasthenia, Bernard-Soulier syndrome, and platelet-type von Willebrand's disease. Curr Opin Hematol 1994;1:388-393.
299. Gassmann W, Loffler H. Acute megakaryoblastic leukemia. Leuk Lymphoma 1995;18:69-73.
300. Von Dem Borne AEG, Modderman PW. Cluster report: CD42. In: Knapp W, Dörken B, Rieber EP, et al., editors. Leucocyte Typing IV White Cell Differentiation Antigens. Oxford: Oxford University Press; 1989. p 1000-1002.
301. Nieuwenhuis HK. Report on functional studies. In: Knapp W, Dörken B, Rieber EP, et al., editors. Leucocyte Typing IV White Cell Differentiation Antigens. Oxford: Oxford University Press; 1989. p 1002-1003.
302. Modderman PW. Cluster report: CD61. In: Knapp W, Dörken B, Rieber EP, et al., editors. Leucocyte Typing IV White Cell Differentiation Antigens. Oxford: Oxford University Press; 1989. p 1025.
303. Law HK, Bol SJ, Palatsides M, Williams NT. Analysis of human megakaryocytic cells using dual-color immunofluorescence labeling. Cytometry 2000;41:308-315.
304. Kafer G, Willer A, Ludwig W, Kramer A, Hehlmann R, Hastka J. Intracellular expression of CD61 precedes surface expression. Ann Hematol 1999;78:472-474. (Pubitemid 29504984)
305. Anstee DJ, Lisowska E. Monoclonal antibodies against glycophorins and other glycoproteins. J Immunogenet 1990;17: 301-308.
306. Cartron JP, Rahuel C. Human erythrocyte glycophorins: Protein and gene structure analyses. Transfus Med Rev 1992;6:63-92.
307. Chasis JA, Mohandas N. Red blood cell glycophorins. Blood 1992;80:1869-1879.
308. Van Der Schoot CE, Baardman R, Lighthart P, et al. CD235a and CD235b - Glycophorin A and Glycophorin B. In: Mason D, Andre P, Bensussan A, et al., editors. Leucocyte Typing VII White Cell Differentiation Antigens. Proceedings of the Seventh International Workshop and Conference held in Harrogate, United Kingdom. New York, NY: Oxford University Press; 2002. p 577-579.
309. Loken MR, Civin CI, Bigbee WL, Langlois RG, Jensen RH. Coordinate glycosylation and cell surface expression of glycophorin A during normal human erythropoiesis. Blood 1987;70:1959-1961. (Pubitemid 18055650)
310. Loken MR, Shah VO, Dattilio KL, Civin CI. Flow cytometric analysis of human bone marrow: I. Normal erythroid development. Blood 1987;69:255-263.
311. Sadahira Y, Kanzaki A, Wada H, Yawata Y. Immunohistochemical identification of erythroid precursors in paraffin embedded bone marrow sections: Spectrin is a superior marker to glycophorin. J Clin Pathol 1999;52:919-921. (Pubitemid 30005367)
312. Chakrabarti A, Kelkar DA, Chattopadhyay A. Spectrin organization and dynamics: New insights. Biosci Rep 2006;26:369-386. (Pubitemid 44777532)
313. Mohandas N, An X. New insights into function of red cell membrane proteins and their interaction with spectrin-based membrane skeleton. Transfus Clin Biol 2006;13:29-30.
314. Gallagher PG. Hereditary elliptocytosis: Spectrin and protein 4.1R. Semin Hematol 2004;41:142-164.
315. Scholzen T, Gerdes J. The Ki-67 protein: From the known and the unknown. J Cell Physiol 2000;182:311-322.
316. Bryant RJ, Banks PM, O'Malley DP. Ki67 staining pattern as a diagnostic tool in the evaluation of lymphoproliferative disorders. Histopathology 2006;48:505-515.
317. Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): A dancer with many partners. J Cell Sci 2003;116:3051-3060. (Pubitemid 37038954)
318. Deptala A, Mayer SP. Detection of minimal residual disease. Methods Cell Biol 2001;64:385-420.
319. Paietta E. Assessing minimal residual disease (MRD) in leukemia: A changing definition and concept? Bone Marrow Transplant 2002;29:459-465.
320. Schuler F, Dolken G. Detection and monitoring of minimal residual disease by quantitative real-time PCR. Clin Chim Acta 2006;363:147-156. (Pubitemid 41748206)
321. Spurbeck JL, Adams SA, Stupca PJ, Dewald GW. Primer on medical genomics. Part XI: Visualizing human chromosomes. Mayo Clin Proc 2004;79:58-75.
322. Smeets DF. Historical prospective of human cytogenetics: From microscope to microarray. Clin Biochem 2004;37:439-446.
323. Swansbury J. Introduction to the analysis of the human G-banded karyotype. Methods Mol Biol 2003;220:259-269.
324. Sumner AT. The nature and mechanisms of chromosome banding. Cancer Genet Cytogenet 1982;6:59-87.
325. Schrock E, du Manoir S, Veldman T, et al. Multicolor spectral karyotyping of human chromosomes. Science 1996;273: 494-497.
326. Bayani J, Squire JA. Spectral karyotyping. Methods Mol Biol 2002;204:85-104.
327. Van Stedum S, King W. Basic FISH techniques and trouble-shooting. Methods Mol Biol 2002;204:51-63.
328. Min T, Swansbury J. Cytogenetic studies using FISH: Background. Methods Mol Biol 2003;220:173-191.
329. Levsky JM, Singer RH. Fluorescence in situ hybridization: Past, present and future. J Cell Sci 2003;116:2833-2838. (Pubitemid 36926972)
330. Liehr T, Starke H, Weise A, Lehrer H, Claussen U. Multicolor FISH probe sets and their applications. Histol Histopathol 2004;19:229-237. (Pubitemid 38111267)
331. Jain KK. Current status of fluorescent in-situ hybridisation. Med Device Technol 2004;15:14-17.
332. Liebisch P, Viardot A, Bassermann N, et al. Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma. Br J Haematol 2003;122:193-201. (Pubitemid 36859603)
333. Cady FM, Muto DN, Ciabeterri G, Johns A, Gainey Church K, Wolff DJ. Utility of interphase FISH panels for routine clinical cytogenetic evaluation of chronic lymphocytic leukemia and multiple myeloma. J Assoc Genet Technol 2004;30:77-81.
334. Nilsson T, Lenhoff S, Rylander L, et al. High frequencies of chromosomal aberrations in multiple myeloma and monoclonal gammopathy of undetermined significance in direct chromosome preparation. Br J Haematol 2004;126:487-494. (Pubitemid 39093090)
335. Bergsagel PL. Prognostic factors in multiple myeloma: It's in the genes. Clin Cancer Res 2003;9:533-534.
336. Dewald GW. Cytogenetic and FISH studies in myelodysplasia, acute myeloid leukemia, chronic lymphocytic leukemia and lymphoma. Int J Hematol 2002;76:65-74.
337. Najfeld V. Diagnostic application of FISH to hematological malignancies. Cancer Invest 2003;21:807-814. (Pubitemid 37377336)
338. Spagnolo DV, Ellis DW, Juneja S, et al. The role of molecular studies in lymphoma diagnosis: A review. Pathology 2004;36:19-44. (Pubitemid 38228417)
339. Steensma DP, List AF. Genetic testing in the myelodysplastic syndromes: Molecular insights into hematologic diversity. Mayo Clin Proc 2005;80:681-698. (Pubitemid 40628827)
340. Bagg A, Kallakury BV. Molecular pathology of leukemia and lymphoma. Am J Clin Pathol 1999;112:S76-S92.
341. Ding C, Cantor CR. Quantitative analysis of nucleic acids - The last few years of progress. J Biochem Mol Biol 2004;37:1-10. (Pubitemid 38402569)
342. Erlich HA. Principles and applications of the polymerase chain reaction. Rev Immunogenet 1999;1:127-134.
343. Jaffe ES, Harris NL, Stein H, editors. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid tissues (World Health Organization Classification of Tumours: 3). Lyon, France: International Agency for Research on Cancer; 2001.
344. Anastasi J. Genetic and molecular genetic studies in the diagnosis of myeloid diseases. Hum Pathol 2003;34:306-313. (Pubitemid 36535011)
345. Fenk R, Haas R, Kronenwett R. Molecular monitoring of minimal residual disease in patients with multiple myeloma. Hematology 2004;9:17-33. (Pubitemid 38256008)
346. Paschka P, Merx K, Hochhaus A. Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - Evaluation of response and resistance. Acta Haematol 2004;112:85-92. (Pubitemid 38716253)
347. Frater JL, Tallman MS, Variakojis D, et al. Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status. Am J Clin Pathol 2003;119:833-841. (Pubitemid 37047845)
348. Kim YJ, Kim DW, Lee S, et al. Comprehensive comparison of FISH, RT-PCR, and RQ-PCR for monitoring the BCR-ABL gene after hematopoietic stem cell transplantation in CML. Eur J Haematol 2002;68:272-280. (Pubitemid 34888454)
349. Schoch C, Schnittger S, Bursch S, et al. Comparison of chromosome banding analysis, interphase- and hypermetaphase- FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: A study on 350 cases. Leukemia 2002;16:53-59. (Pubitemid 34105599)
350. Marshall GM, Haber M, Kwan E, et al. Importance of minimal residual disease testing during the second year of therapy for children with acute lymphoblastic leukemia. J Clin Oncol 2003;21:704-709. (Pubitemid 46621906)
351. Cross NC. Quantitative PCR techniques and applications. Br J Haematol 1995;89:693-697.
352. Schiffer CA, Hehlmann R, Larson R. Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1). Leukemia 2003;17:691-699.
353. Bagg A. Commentary: Minimal residual disease: How low do we go? Mol Diagn 2001;6:155-160.
354. Markoulatos P, Siafakas N, Moncany M. Multiplex polymerase chain reaction: A practical approach. J Clin Lab Anal 2002; 16:47-51. (Pubitemid 34075921)
355. van der Velden VH, Jacobs DC, Wijkhuijs AJ, et al. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia 2002;16: 1432-1436.
356. Wu CJ, Neuberg D, Chillemi A, et al. Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk Lymphoma 2002;43:2281-2289. (Pubitemid 35390333)
357. Bertheas MF, Lafage M, Levy P, et al. Influence of mixed chimerism on the results of allogeneic bone marrow transplantation for leukemia. Blood 1991;78:3103-3106.
358. McCann SR, Lawler M. Mixed chimaerism; Detection and significance following BMT. Bone Marrow Transplant 1993;11 :91-94.
359. Price CM, Colman SM, Kanfer EJ. Persistence of multilineage host haemopoiesis following allogeneic bone marrow transplantation. Br J Haematol 1995;90:465-468.
360. Huss R, Deeg HJ, Gooley T, et al. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant 1996;18:767-776. (Pubitemid 26361366)